TY - JOUR
T1 - Progression after molecular targeted agents
T2 - Hepatic arterial changes and transarterial chemoembolization in hepatocellular carcinoma
AU - Matsuda, Noritaka
AU - Imai, Norihiro
AU - Kuzuya, Teiji
AU - Yamamoto, Kenta
AU - Takanori, I. T.O.
AU - Ishizu, Yoji
AU - Honda, Takashi
AU - Ishigami, Masatoshi
AU - Fujishiro, Mitsuhiro
N1 - Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Background/Aim: The purpose of this study was to determine changes in the hepatic arteries after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy of transarterial chemoembolization (TACE) as a post-MTA treatment in patients with hepatocellular carcinoma (HCC). Patients and Methods: The cases of 33 patients with intermediate HCC treated with MTA and TACE were studied retrospectively. The hepatic arteries, and the safety and efficacy of TACE were evaluated before and after MTA treatment. Results: Following long-term MTA treatment, the diameters of hepatic arteries decreased significantly, while there was no difference in the diameters of the splenic artery or the portal vein. No significant adverse events were observed due to TACE after MTA; however, the therapeutic effect of TACE was limited after MTA treatment. Conclusion: This study demonstrated that the diameters of hepatic arteries were significantly smaller than those before MTA induction, suggesting ischemic effects and tumor vessel “normalization” by MTA treatment. Although TACE can be performed as a post-MTA treatment without lowering the hepatic reserve or causing serious complications, its therapeutic effect is limited.
AB - Background/Aim: The purpose of this study was to determine changes in the hepatic arteries after treatment with a molecular targeted agent (MTA), and evaluate the safety and efficacy of transarterial chemoembolization (TACE) as a post-MTA treatment in patients with hepatocellular carcinoma (HCC). Patients and Methods: The cases of 33 patients with intermediate HCC treated with MTA and TACE were studied retrospectively. The hepatic arteries, and the safety and efficacy of TACE were evaluated before and after MTA treatment. Results: Following long-term MTA treatment, the diameters of hepatic arteries decreased significantly, while there was no difference in the diameters of the splenic artery or the portal vein. No significant adverse events were observed due to TACE after MTA; however, the therapeutic effect of TACE was limited after MTA treatment. Conclusion: This study demonstrated that the diameters of hepatic arteries were significantly smaller than those before MTA induction, suggesting ischemic effects and tumor vessel “normalization” by MTA treatment. Although TACE can be performed as a post-MTA treatment without lowering the hepatic reserve or causing serious complications, its therapeutic effect is limited.
UR - http://www.scopus.com/inward/record.url?scp=85101929194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101929194&partnerID=8YFLogxK
U2 - 10.21873/INVIVO.12367
DO - 10.21873/INVIVO.12367
M3 - Article
C2 - 33622919
AN - SCOPUS:85101929194
SN - 0258-851X
VL - 35
SP - 1185
EP - 1189
JO - In Vivo
JF - In Vivo
IS - 2
ER -